{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:05:10Z","timestamp":1793862310330,"version":"4.6.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Special Scientific Research Funding Project for Comprehensive Clinical Evaluation of Drugs by Zhejiang Pharmaceutical Association","award":["2024ZYYL04"],"award-info":[{"award-number":["2024ZYYL04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triazole antifungal drugs (TADs) are widely used in clinical practice but carry a risk of severe cutaneous adverse reactions (SCARs). However, comprehensive real-world evidence regarding the comparative safety profiles of individual TADs remains limited. This research aimed to investigate and compare the real-world risk, clinical characteristics, and time-to-onset of SCARs associated with individual TADs. The SCAR cases with TADs as the primary suspect drug were identified in the FDA Adverse Event Reporting System. Disproportionality analysis and Bayesian methods were employed to detect safety signals with Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM). Differences of clinical features, outcomes, time-to-onset (TTO), and signal strength at the preferred term (PT) level were analyzed. A total of 1429 SCAR cases with five TADs were identified. Fluconazole showed the strongest and most consistent statistical association across all four algorithms (ROR = 5.2), followed by itraconazole. Voriconazole yielded mixed signals (positive by ROR and BCPNN only), while Posaconazole and Isavuconazole exhibited no significant SCAR signals. Voriconazole was associated with the highest mortality proportion (12.8%), followed by posaconazole (10%). The median TTO for SCARs was 8 days, with voriconazole having the longest delay (16 days). At the PT level, 45 distinct signals were identified, including high-risk manifestations such as fixed eruption (ROR = 24.43), mucosal ulceration, and SJS\/TEN overlap. This study identified significant variability of SCARs signals among triazole antifungals. These findings support early risk recognition and informed antifungal selection in clinical practice.<\/jats:p>","DOI":"10.1093\/mmy\/myag084","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:29:06Z","timestamp":1786706946000},"source":"Crossref","is-referenced-by-count":1,"title":["A retrospective study comparing the severe cutaneous adverse reactions in patients receiving triazole antifungal therapy and literature analysis"],"prefix":"10.1093","volume":"64","author":[{"given":"Cheng-Tao","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou 310016 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Traditional Chinese Medicine Hospital of Changshan , Quzhou 324200 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital , Quzhou 324000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7152-7611","authenticated-orcid":false,"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People\u2019s Hospital , Quzhou 324000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026082415511808000_bib1","doi-asserted-by":"publisher","first-page":"832048","DOI":"10.3389\/fphar.2022.832048","article-title":"Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics","volume":"13","author":"Tempark","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"2026082415511808000_bib2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4168\/aair.2019.11.2.241","article-title":"Severe cutaneous adverse reactions in Korean pediatric patients: a study from the Korea SCAR registry","volume":"11","author":"Oh","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"2026082415511808000_bib3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.18176\/jiaci.0497","article-title":"Severe cutaneous adverse reactions to drugs in Latin America: the RACGRAD study","volume":"31","author":"Rojas\u00a0Mej\u00eda","year":"2021","journal-title":"J Investig Allergol Clin. Immunol"},{"key":"2026082415511808000_bib4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026082415511808000_bib5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"issue":"4","key":"2026082415511808000_bib6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.mjafi.2013.01.007","article-title":"Severe cutaneous adverse drug reactions","volume":"69","author":"Verma","year":"2013","journal-title":"Med J Armed Forces India"},{"issue":"9","key":"2026082415511808000_bib7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14740338.2021.1922667","article-title":"Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions","volume":"20","author":"Tragiannidis","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2026082415511808000_bib8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14656566.2021.1996562","article-title":"Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections","volume":"23","author":"Panagopoulou","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"2026082415511808000_bib9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026082415511808000_bib10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2026082415511808000_bib11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/DER.0000000000000451","article-title":"Herpes simplex-like fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole","volume":"30","author":"Schneller-Pavelescu","year":"2019","journal-title":"Dermatitis"},{"issue":"3","key":"2026082415511808000_bib12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/jac\/dky501","article-title":"Tolerability of long-term fluconazole therapy","volume":"74","author":"Davis","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2026082415511808000_bib13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cod.12513","article-title":"Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole","volume":"74","author":"Nasir","year":"2016","journal-title":"Contact Dermatitis"},{"issue":"4","key":"2026082415511808000_bib14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"2026082415511808000_bib15","first-page":"e172","article-title":"Therapeutic tools for oral candidiasis: Current and new antifungal drugs","volume":"24","author":"Quind\u00f3s","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"12","key":"2026082415511808000_bib16","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT interval prolongation: pointes of interest","volume":"43","author":"Owens","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2026082415511808000_bib17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","article-title":"QT prolongation with antimicrobial agents: understanding the significance","volume":"64","author":"Owens","year":"2004","journal-title":"Drugs"},{"issue":"2","key":"2026082415511808000_bib18","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1097\/JS9.0000000000003667","article-title":"Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of the FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report databases, and the role of pharmacists","volume":"112","author":"Li","year":"2026","journal-title":"Int J Surg"},{"issue":"3","key":"2026082415511808000_bib19","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1097\/JS9.0000000000004467","article-title":"Anticoagulant-associated bleeding: real-world data-driven pharmacovigilance and insights for bleeding management","volume":"112","author":"Hong","year":"2026","journal-title":"Int J Surg"},{"key":"2026082415511808000_bib20","doi-asserted-by":"publisher","first-page":"178278","DOI":"10.1016\/j.ejphar.2025.178278","article-title":"Postmarketing safety signals of cetuximab and panitumumab in the FAERS database: real-World insights focus on population heterogeneity","volume":"1007","author":"Mao","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"2026082415511808000_bib21","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2026082415511808000_bib22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2026082415511808000_bib23","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/jcpt.13472","article-title":"Thyroid dysfunction related to vascular endothelial growth factor receptor tyrosine kinase inhibitors: A real-world study based on FAERS","volume":"46","author":"Liao","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"7","key":"2026082415511808000_bib24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"3","key":"2026082415511808000_bib25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","article-title":"Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 Years","volume":"43","author":"Song","year":"2020","journal-title":"Oncol Res Treat"},{"key":"2026082415511808000_bib26","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"2026082415511808000_bib27","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026082415511808000_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/ijd.IJD_591_17","article-title":"Recent advances in severe cutaneous adverse drug reaction","volume":"63","author":"Das","year":"2018","journal-title":"Indian J Dermatol"},{"key":"2026082415511808000_bib29","first-page":"1","article-title":"Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database","author":"Shan","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026082415511808000_bib30","doi-asserted-by":"publisher","first-page":"1039867","DOI":"10.3389\/fphar.2022.1039867","article-title":"Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026082415511808000_bib31","doi-asserted-by":"publisher","first-page":"20420986221143266","DOI":"10.1177\/20420986221143266","article-title":"Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS","volume":"13","author":"Chai","year":"2022","journal-title":"Ther Adv Drug Saf"},{"issue":"8759","key":"2026082415511808000_bib32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0140-6736(91)90112-3","article-title":"Stevens-Johnson syndrome after fluconazole","volume":"338","author":"Gussenhoven","year":"1991","journal-title":"Lancet"},{"issue":"11","key":"2026082415511808000_bib33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/01.SMJ.0000144618.80128.F9","article-title":"Toxic epidermal necrolysis as a complication of treatment with voriconazole","volume":"97","author":"Huang","year":"2004","journal-title":"South Med J"},{"issue":"7","key":"2026082415511808000_bib34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/annonc\/mdj126","article-title":"Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy","volume":"17","author":"Curigliano","year":"2006","journal-title":"Ann Oncol"},{"issue":"9","key":"2026082415511808000_bib35","doi-asserted-by":"publisher","first-page":"13030\/qt2pt32578","DOI":"10.5070\/D3209023901","article-title":"Toxic epidermal necrolysis due to voriconazole: case report and review","volume":"20","author":"Gomulka","year":"2014","journal-title":"Dermatol Online J"},{"issue":"5","key":"2026082415511808000_bib36","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1111\/1346-8138.14142","article-title":"Agranulocytosis associated with voriconazole-induced hypersensitivity syndrome","volume":"45","author":"Kaneko","year":"2018","journal-title":"J Dermatol"},{"issue":"4","key":"2026082415511808000_bib37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated stevens-johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2026082415511808000_bib38","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1097\/JS9.0000000000003667","article-title":"Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of FDA adverse event reporting system database and Japanese adverse drug event report database, and the role of pharmacists","volume":"112","author":"Li","year":"2026","journal-title":"Int J Surg"},{"key":"2026082415511808000_bib39","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/IJGM.S460305","article-title":"Statin-associated liver dysfunction and muscle injury: epidemiology, mechanisms, and management strategies","volume":"17","author":"Ma","year":"2024","journal-title":"Int J Gen Med"},{"issue":"2","key":"2026082415511808000_bib40","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ddr.22025","article-title":"Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev Res"},{"issue":"11","key":"2026082415511808000_bib41","doi-asserted-by":"publisher","first-page":"45077","DOI":"10.31083\/RCM45077","article-title":"Bleeding in antiplatelet therapy: a narrative review of clinical evidence and the roles of pharmacists and nurses","volume":"26","author":"Xu","year":"2025","journal-title":"Rev Cardiovasc Med"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myag084\/70665251\/myag084.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/64\/8\/myag084\/70665251\/myag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/64\/8\/myag084\/70665251\/myag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:51:26Z","timestamp":1787601086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myag084\/8762561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myag084","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"myag084"}}